Thursday, August 6, 2015

Sangamo Presenting at Stem Cell on the Mesa October 7-9 2015

The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the interests of the advanced therapies and regenerative medicine community, today announced the initial slate of companies selected to present at its upcoming Stem Cell Meeting on the Mesa (SCMOM) Partnering Forum.
The meeting will feature presentations from more than 60 leading companies in the fields of cell therapy, gene and gene-modified cell therapy and tissue engineering. The Partnering Forum will take place October 7 and 8, 2015 at the Estancia Hotel in La Jolla, California as part of the full SCMOM conference, which also features a Scientific Symposium on October 9, 2015.
Collectively, the initial slate of presenting companies are currently conducting 125+ clinical trials with an additional 130 studies in the pre-clinical or research phase and 15+ products on the market. Altogether, these companies are developing 165+ unique products across a range of possible therapeutic applications.
Initial slate of presenting companies:
Abeona Therapeutics, Argos Therapeutics, Asterias Biotherapeutics, Avalanche Biotech, BioLife Solutions, bluebird bio, BrainStorm Cell Therapeutics, Caladrius Biosciences, Capricor Therapeutics, Cellectis, Cell Therapy Ltd., Cellular Dynamics International, Celyad, Cesca Therapeutics, Cyfuse, DiscGenics, Editas Medicine, Fate Therapeutics, Fibrocell Science, GenVec, HemoStemix, Histogenics, Inovio Pharmaceuticals, InVivo Therapeutics, jCyte, Juventas Therapeutics, Kiadis Pharma, MaxCyte, MEDIPOST America, Mesoblast Ltd., MiMedx, MolMed, Opexa Therapeutics, Organovo, Orthocell, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, Regenerative Patch Technologies, REGENXBIO, ReNeuron, RepliCel, Sangamo BioSciences, StemBioSys, StemCells, Inc., TaiwanBio, Terumo BCT, TiGenix, TissueGene, uniQure, Vericel, ViaCyte, Voyager Therapeutics


Read more: http://www.digitaljournal.com/pr/2636604#ixzz3i2Ob3mZ5

No comments:

Post a Comment